{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:05:19Z","timestamp":1791212719323,"version":"4.1.0"},"reference-count":52,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2017,12,21]],"date-time":"2017-12-21T00:00:00Z","timestamp":1513814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Glecaprevir (formerly ABT-493) is a novel hepatitis C virus (HCV) NS3\/4A protease inhibitor (PI) with pangenotypic activity. It inhibited the enzymatic activity of purified NS3\/4A proteases from HCV genotypes 1 to 6\n            <jats:italic>in vitro<\/jats:italic>\n            (half-maximal [50%] inhibitory concentration = 3.5 to 11.3 nM) and the replication of stable HCV subgenomic replicons containing proteases from genotypes 1 to 6 (50% effective concentration [EC\n            <jats:sub>50<\/jats:sub>\n            ] = 0.21 to 4.6 nM). Glecaprevir had a median EC\n            <jats:sub>50<\/jats:sub>\n            of 0.30 nM (range, 0.05 to 3.8 nM) for HCV replicons containing proteases from 40 samples from patients infected with HCV genotypes 1 to 5. Importantly, glecaprevir was active against the protease from genotype 3, the most-difficult-to-treat HCV genotype, in both enzymatic and replicon assays demonstrating comparable activity against the other HCV genotypes. In drug-resistant colony selection studies, glecaprevir generally selected substitutions at NS3 amino acid position A156 in replicons containing proteases from genotypes 1a, 1b, 2a, 2b, 3a, and 4a and substitutions at position D\/Q168 in replicons containing proteases from genotypes 3a, 5a, and 6a. Although the substitutions A156T and A156V in NS3 of genotype 1 reduced susceptibility to glecaprevir, replicons with these substitutions demonstrated a low replication efficiency\n            <jats:italic>in vitro<\/jats:italic>\n            . Glecaprevir is active against HCV with most of the common NS3 amino acid substitutions that are associated with reduced susceptibility to other currently approved HCV PIs, including those at positions 155 and 168. Combination of glecaprevir with HCV inhibitors with other mechanisms of action resulted in additive or synergistic antiviral activity. In summary, glecaprevir is a next-generation HCV PI with potent pangenotypic activity and a high barrier to the development of resistance.\n          <\/jats:p>","DOI":"10.1128\/aac.01620-17","type":"journal-article","created":{"date-parts":[[2017,10,30]],"date-time":"2017-10-30T15:50:31Z","timestamp":1509378631000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":79,"title":["<i>In Vitro<\/i>\n            Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3\/4A Protease Inhibitor Glecaprevir"],"prefix":"10.1128","volume":"62","author":[{"given":"Teresa I.","family":"Ng","sequence":"first","affiliation":[{"name":"AbbVie, Inc., North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Tripathi","sequence":"additional","affiliation":[{"name":"AbbVie, Inc., North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Reisch","sequence":"additional","affiliation":[{"name":"AbbVie, Inc., North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangjun","family":"Lu","sequence":"additional","affiliation":[{"name":"AbbVie, Inc., North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Middleton","sequence":"additional","affiliation":[{"name":"AbbVie, Inc., North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd A.","family":"Hopkins","sequence":"additional","affiliation":[{"name":"AbbVie, Inc., North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Pithawalla","sequence":"additional","affiliation":[{"name":"AbbVie, Inc., North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Irvin","sequence":"additional","affiliation":[{"name":"AbbVie, Inc., North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Dekhtyar","sequence":"additional","affiliation":[{"name":"AbbVie, Inc., North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preethi","family":"Krishnan","sequence":"additional","affiliation":[{"name":"AbbVie, Inc., North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gretja","family":"Schnell","sequence":"additional","affiliation":[{"name":"AbbVie, Inc., North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Beyer","sequence":"additional","affiliation":[{"name":"AbbVie, Inc., North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith F.","family":"McDaniel","sequence":"additional","affiliation":[{"name":"AbbVie, Inc., North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ma","sequence":"additional","affiliation":[{"name":"Enanta Pharmaceuticals Inc., Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Enanta Pharmaceuticals Inc., Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Juan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Enanta Pharmaceuticals Inc., Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yat Sun","family":"Or","sequence":"additional","affiliation":[{"name":"Enanta Pharmaceuticals Inc., Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale","family":"Kempf","sequence":"additional","affiliation":[{"name":"AbbVie, Inc., North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tami","family":"Pilot-Matias","sequence":"additional","affiliation":[{"name":"AbbVie, Inc., North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Collins","sequence":"additional","affiliation":[{"name":"AbbVie, Inc., North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27259"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.07.027"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26744"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02831-14"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.68.8.5045-5055.1994"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3253"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1021\/ml500070q"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13027"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.06.004"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002832"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.03.030"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2013.06.014"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01953-15"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.04.003"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00051-16"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.7326\/M16-2575"},{"key":"e_1_3_2_18_2","volume-title":"American Association for the Study of Liver Diseases","author":"American Association for the Study of Liver Diseases and Infectious Diseases Society of America","year":"2017","unstructured":"American Association for the Study of Liver Diseases and Infectious Diseases Society of America. 2017. Hepatitis C guidance: recommendations for testing, managing, and treating hepatitis C virus. American Association for the Study of Liver Diseases, Alexandria, VA, and Infectious Diseases Society of America, Arlington, VA. http:\/\/www.hcvguidelines.org."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.09.001"},{"key":"e_1_3_2_20_2","volume-title":"Zepatier (elbasvir and grazoprevir) tablets, for oral use package insert","author":"Merck & Co., Inc","year":"2016","unstructured":"Merck & Co., Inc. 2016. Zepatier (elbasvir and grazoprevir) tablets, for oral use package insert. Merck & Co., Inc., Whitehouse Station, NJ."},{"key":"e_1_3_2_21_2","first-page":"1393A","article-title":"Prevalence and impact of baseline NS5A resistance-associated variants (RAVs) on the efficacy of elbasvir\/grazoprevir (EBR\/GZR) against GT1a infection","volume":"62","author":"Jacobson IM","year":"2015","unstructured":"Jacobson IM, Asante-Appiah E, Wong P, Black T, Howe A, Wahl J, Robertson MN, Nguyen B-Y, Shaughnessy M, Hwang P, Barr E, Hazuda D. 2015. Prevalence and impact of baseline NS5A resistance-associated variants (RAVs) on the efficacy of elbasvir\/grazoprevir (EBR\/GZR) against GT1a infection. Hepatology 62:1393A\u20131394A.","journal-title":"Hepatology"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26388"},{"key":"e_1_3_2_23_2","volume-title":"Highlights of prescribing information","author":"Janssen Products","year":"2013","unstructured":"Janssen Products. 2013. Olysio (simeprevir). Highlights of prescribing information. Janssen Therapeutics, Titusville, NJ."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2012.12.020"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27934"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(17)31399-5"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(17)31927-X"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01390-15"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04227-14"},{"key":"e_1_3_2_30_2","volume-title":"Abstr Int Conf Viral Hepatitis","author":"Chase R","year":"2013","unstructured":"Chase R, Black S, McMonagle P, Guo Z, Curry S, Nachbar R, Howe AYM, Howe JA. 2013. Characterization of resistance associated variants selected in GT1, GT2, and GT3 replicons by the HCV NS3\/4A protease inhibitor MK5172, abstr 25. Abstr Int Conf Viral Hepatitis, New York, NY."},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00324-12"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01229-15"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)31102-8"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02558-16"},{"key":"e_1_3_2_35_2","volume-title":"MacSynergy II, v1.0","author":"Prichard MN","year":"1993","unstructured":"Prichard MN, Aseltine KR, Shipman C, Jr. 1993. MacSynergy II, v1.0. University of Michigan, Ann Arbor, MI."},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(17)30326-4"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep20310"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01976-13"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2015.02.005"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0163197"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2013.04.018"},{"key":"e_1_3_2_42_2","volume-title":"Application number 208261Orig1s000, Zepatier microbiology\/virology review","author":"U.S. Food and Drug Administration, Center for Drug Evaluation and Research","year":"2016","unstructured":"U.S. Food and Drug Administration, Center for Drug Evaluation and Research. 2016. Application number 208261Orig1s000, Zepatier microbiology\/virology review. U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Rockville, MD. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/208261Orig1s000MicroR.pdf. Accessed 6 July 2017."},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.09.027"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02264-15"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29081"},{"key":"e_1_3_2_46_2","first-page":"132A","article-title":"ENDURANCE-1: a phase 3 evaluation of the efficacy and safety of 8- versus 12-week treatment with glecaprevir\/pibrentasvir (formerly ABT-493\/ABT-530) in HCV genotype 1 infected patients with or without HIV-1 co-infection and without cirrhosis","volume":"64","author":"Zeuzem S","year":"2016","unstructured":"Zeuzem S, Feld J, Wang S, Bourliere M, Wedemeyer H, Gane E, Flisiak R, Chuang WL, Flamm S, Kwo P, Sepulveda-Arzola G, Soto-Malave R, Puoti M, Tam E, Bruck R, Fuster F, Paik SW, Felizarta F, Fu B, Ng TI, Lin CW, Mensa F. 2016. ENDURANCE-1: a phase 3 evaluation of the efficacy and safety of 8- versus 12-week treatment with glecaprevir\/pibrentasvir (formerly ABT-493\/ABT-530) in HCV genotype 1 infected patients with or without HIV-1 co-infection and without cirrhosis. Hepatology 64(Suppl 1):132A\u2013133A.","journal-title":"Hepatology"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30496-6"},{"key":"e_1_3_2_48_2","first-page":"1125A","article-title":"EXPEDITION-4: efficacy and safety of glecaprevir\/pibrentasvir (ABT-493\/ABT-530) in patients with renal impairment and chronic hepatitis C virus genotype 1-6 infection","volume":"64","author":"Gane E","year":"2016","unstructured":"Gane E, Lawitz E, Pugatch D, Papatheodoridis G, Br\u00e4u N, Brown A, Pol S, Leroy V, Persico M, Moreno C, Colombo M, Yoshida EM, Nelson DR, Lei Y, Kosloski M, Mensa F. 2016. EXPEDITION-4: efficacy and safety of glecaprevir\/pibrentasvir (ABT-493\/ABT-530) in patients with renal impairment and chronic hepatitis C virus genotype 1-6 infection. Hepatology 64(Suppl 1):1125A.","journal-title":"Hepatology"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1086\/515683"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2007.06.020"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.285.5424.110"},{"key":"e_1_3_2_52_2","first-page":"9","article-title":"Analysis of combinations of antiviral drugs and design of effective multidrug therapies","volume":"1","author":"Prichard MN","year":"1996","unstructured":"Prichard MN, Shipman C, Jr. 1996. Analysis of combinations of antiviral drugs and design of effective multidrug therapies. Antivir Ther 1:9\u201320.","journal-title":"Antivir Ther"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.3.540"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01620-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01620-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:08:09Z","timestamp":1645477689000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01620-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.1128\/AAC.01620-17"],"URL":"https:\/\/doi.org\/10.1128\/aac.01620-17","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"2017-08-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-10-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-12-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01620-17"}}